Clinical Trial Update: A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease [Phase 4]

View source ↗

Summary

The Phase 4 trial evaluating Eligard (leuprolide acetate) in metastatic prostate cancer, focusing on disease biomarkers in blood and urine, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Eligard (leuprolide acetate)

Snippet

Sponsor: Astellas Pharma Europe Ltd. | Conditions: Metastatic Prostate Cancer | Phase 4 | Status: TERMINATED